Raymond Phillips
Naples, FLNPI 1437155231
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Janssen Research & Development, LLC at 34.8% of the total. Reporting peaked in 2024 at $1,520 and has fallen 88.0% since, to $182 in 2025.
Across 87 payments — averaging $48.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- AbbVie$685
- Johnson & Johnson$390
- Gilead$302
- Janssen Scientific Affairs, LLC$282
- Sanofi$249
- plus $843 from 13 others
Across 992 payments — averaging $1909.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$611K
- Takeda Pharmaceuticals U.S.A., Inc.$474K
- Gilead$295K
- Boehringer Ingelheim International GmbH$155K
- AstraZeneca$77K
- Vectivbio AG$65K
- plus $218K from 11 others
What the payments were for
- Consulting fees$1,47035%
- Food & beverage$2,44858%
- Education$3047%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 1 | $1,470 |
| AbbVie(2 entities) | 33 | $685 |
| Johnson & Johnson | 10 | $390 |
| Gilead | 5 | $302 |
| Janssen Scientific Affairs, LLC | 4 | $282 |
| Sanofi | 2 | $249 |
| Genentech, Inc. | 1 | $127 |
| Ferring Pharmaceuticals Inc. | 1 | $115 |
| Bristol Myers Squibb | 6 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $91 |
| Merck | 4 | $69 |
| Pfizer | 3 | $62 |
| Ironwood Pharmaceuticals, Inc | 3 | $45 |
| Shionogi Inc | 2 | $34 |
| Boston Scientific | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $17 |
| Vivus LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.